Analysis Group Announces Collaboration to Advance Hematology Research in China

November 14, 2019

Analysis Group has formed a strategic partnership with the Institute of Hematology & Blood Diseases Hospital (IHBDH), a research institute and hospital affiliated with the Chinese Academy of Medical Sciences and Peking Union Medical College, to advance hematology research based on real-world evidence (RWE) in China. The two organizations will partner to create the National Longitudinal Cohort of Hematological Diseases in China (NICHE), the country’s first comprehensive blood disease research platform. Analysis Group will work closely with IHBDH to advise on best practices for designing, building, and maintaining the platform, which will address research needs in acute myeloid leukemia, lymphoma, multiple myeloma, hemophilia, pediatric hematological diseases, and other blood diseases.

Lack of high-quality medical information remains the most significant roadblock to the ongoing evolution of China’s health care system. Different population and environmental characteristics between China and other countries create unique challenges that can only be addressed using China-specific data.

Analysis Group and IHBDH aim to remove this obstacle by populating NICHE with high-quality RWE from more than 10,000 patients across the 140 public hospitals in the China Alliance for Blood Diseases, which span the country’s 30 provinces. This will represent the largest longitudinal hematological cohort from which real-world evidence has been generated. The information gathered will create the foundation needed to conduct research to drive innovation in treatment and prevention, improve quality of care and patient outcomes, facilitate clinical decision making, and inform health policies and regulatory and reimbursement decisions.

“Our goal is to set up a world-class hematological research platform that advances the patient-centric study of hematology in China,” said Eric Wu, managing principal at Analysis Group. “This is a complex challenge that has not been well addressed in China. We are excited to collaborate with IHBDH on this important undertaking.”

A scientific advisory committee, assembled by IHBDH and Analysis Group, will help address key questions related to patient selection criteria, definition of key variables, patient follow-up, information integration, and quality-control best practices. The committee will consist of experts in hematological diseases, health policy, health economics, epidemiology, biostatistics, bioinformatics, biotechnology, and biopharma.

Funding for the research platform has been provided by the Chinese Academy of Medical Sciences. For more information about the platform, please visit www.niche-study.org. Parties interested in using NICHE for their studies can contact Analysis Group at NICHE@analysisgroup.com.